HC Wainwright Reiterates Buy Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $18.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 267.35% from the stock’s previous close.

Several other research analysts have also weighed in on the stock. JMP Securities reissued a “market outperform” rating and set a $21.00 price objective (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Robert W. Baird decreased their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Price Performance

NASDAQ:ENTA opened at $4.90 on Tuesday. The business’s 50-day moving average is $5.94 and its two-hundred day moving average is $9.68. The firm has a market capitalization of $104.52 million, a PE ratio of -0.89 and a beta of 0.54. Enanta Pharmaceuticals has a 12 month low of $4.71 and a 12 month high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. Equities analysts anticipate that Enanta Pharmaceuticals will post -5.05 EPS for the current year.

Insider Buying and Selling at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the transaction, the chief executive officer now directly owns 801,638 shares in the company, valued at $6,461,202.28. The trade was a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 13.89% of the stock is owned by insiders.

Institutional Trading of Enanta Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ENTA. JPMorgan Chase & Co. increased its stake in shares of Enanta Pharmaceuticals by 53.7% in the third quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock valued at $2,524,000 after purchasing an additional 85,082 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of Enanta Pharmaceuticals by 34.1% in the 4th quarter. Assenagon Asset Management S.A. now owns 192,856 shares of the biotechnology company’s stock worth $1,109,000 after buying an additional 49,050 shares in the last quarter. Barclays PLC lifted its holdings in shares of Enanta Pharmaceuticals by 294.2% in the third quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock valued at $285,000 after buying an additional 20,478 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new position in Enanta Pharmaceuticals during the third quarter valued at about $122,000. Finally, Geode Capital Management LLC grew its holdings in Enanta Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock worth $4,946,000 after acquiring an additional 14,575 shares during the period. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.